Parimer Scientific

Executive Summary

Parimer Scientific is a U.S.-based Contract Development and Manufacturing Organization (CDMO) founded in 2018 and headquartered in San Diego. The company specializes in helping startups, researchers, and mid-size companies scale chemical products from the laboratory to full-scale production. Its core services include formulation development, process optimization, and small-batch manufacturing, targeting the diagnostics and medical devices sectors. As a private, pre-clinical stage company, Parimer positions itself as a critical partner for early-stage innovators lacking internal manufacturing capabilities. With a focus on flexibility and speed, it aims to bridge the gap between R&D and commercial manufacturing, addressing a common bottleneck in the chemical product lifecycle. The CDMO market is growing steadily, driven by outsourcing trends and the need for specialized expertise. Parimer's service model serves a high-demand niche, particularly for pre-commercial companies. While the company has not disclosed financials or client pipelines, its continued operation since 2018 suggests a stable client base. Key risks include competition from larger CDMOs and dependence on the success of client products. Near-term catalysts could include major client contract announcements, facility expansions, or quality certifications such as ISO 13485, which would enhance credibility. Overall, Parimer Scientific is positioned for gradual growth, contingent on its ability to secure repeat business and scale with client needs.

Upcoming Catalysts (preview)

• Q3 2026Major Client Contract Award65% success
• Q4 2026Facility Expansion or New Lab Capacity50% success
• Q2 2027ISO 13485 Certification70% success